… In this broader population of atezolizumab-treated patients, … with atezolizumab monotherapy
in more selected populations. Here, we report prespecified analyses of safety and efficacy in …

Purpose: Atezolizumab is an established treatment option for pretreated urothelial carcinoma,
demonstrating efficacy in phase II/III trials. The SAUL study enrolled a broader patient …

… In this international study we investigated the efficacy and safety of atezolizumab treatment
for advanced urinary tract cancer in a large population of pretreated patients, including those …

… The objectives of the study include to report the clinical efficacy and safety of
atezolizumab, and the response to future therapies in clinical practice outside clinical trials. …

… developed rapidly and have demonstrated antitumor activity in various cancers. To
evaluate the safety and efficacy of atezolizumab in treating cancers, we conducted this meta-analysis. …

… Therefore, a higher response to chemotherapy may be observed after converting the
immunosuppressive tumor environment. The results of this study revealed that atezolizumab and …

… of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (…
: 21–41%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the …

… locally advanced or metastatic urothelial carcinoma after progression with platinum-based
chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed …

… , atezolizumab, in patients with bladder cancer who had already received platinum-containing
chemotherapy. This analysis compared the effectiveness of atezolizumab … atezolizumab …

Background Atezo, a monoclonal antibody targeting PD-L1, is an approved therapy for locally
advanced/metastatic urothelial cancer. The pivotal IMvigor210 and IMvigor211 phase II …